{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:09:25Z","timestamp":1790698165457,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["AAP-2017-059"],"award-info":[{"award-number":["AAP-2017-059"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00228-020-02952-7","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T23:06:37Z","timestamp":1594076797000},"page":"1675-1682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4990-5201","authenticated-orcid":false,"given":"C\u00e9cile","family":"Souty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titouan","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Steichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Turbelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Sarazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Vilcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Blanchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hanslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"9","key":"2952_CR1","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1345\/aph.1A333","volume":"36","author":"PJ McDonnell","year":"2002","unstructured":"McDonnell PJ, Jacobs MR (2002) Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36(9):1331\u20131336","journal-title":"Ann Pharmacother"},{"key":"2952_CR2","first-page":"w13522","volume":"142","author":"M Oertle","year":"2012","unstructured":"Oertle M (2012) Frequency and nature of drug-drug interactions in a Swiss primary and secondary acute care hospital. Swiss Med Wkly 142:w13522","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"2952_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00228-015-1974-0","volume":"72","author":"C Pedros","year":"2016","unstructured":"Pedros C, Formiga F, Corbella X, Arnau JM (2016) Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol 72(2):219\u2013226","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2952_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16(6):641\u2013651","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2952_CR5","doi-asserted-by":"publisher","first-page":"e0147606","DOI":"10.1371\/journal.pone.0147606","volume":"11","author":"HC Bucher","year":"2016","unstructured":"Bucher HC, Achermann R, Stohler N, Meier CR (2016) Surveillance of physicians causing potential drug-drug interactions in ambulatory care: a pilot study in Switzerland. PLoS One 11(1):e0147606","journal-title":"PLoS One"},{"issue":"6","key":"2952_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.sapharm.2017.07.004","volume":"14","author":"J Jazbar","year":"2018","unstructured":"Jazbar J, Locatelli I, Horvat N, Kos M (2018) Clinically relevant potential drug-drug interactions among outpatients: a nationwide database study. Res Social Adm Pharm 14(6):572\u2013580","journal-title":"Res Social Adm Pharm"},{"issue":"10","key":"2952_CR7","doi-asserted-by":"publisher","first-page":"e78827","DOI":"10.1371\/journal.pone.0078827","volume":"8","author":"E Tragni","year":"2013","unstructured":"Tragni E, Casula M, Pieri V, Favato G, Marcobelli A, Trotta MG, Catapano AL (2013) Prevalence of the prescription of potentially interacting drugs. PLoS One 8(10):e78827","journal-title":"PLoS One"},{"issue":"3","key":"2952_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/02813430310001806","volume":"21","author":"L Bjerrum","year":"2003","unstructured":"Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21(3):153\u2013158","journal-title":"Scand J Prim Health Care"},{"issue":"9","key":"2952_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00228-006-0143-x","volume":"62","author":"B Astrand","year":"2006","unstructured":"Astrand B, Astrand E, Antonov K, Petersson G (2006) Detection of potential drug interactions - a model for a national pharmacy register. Eur J Clin Pharmacol 62(9):749\u2013756","journal-title":"Eur J Clin Pharmacol"},{"key":"2952_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fphar.2019.00265","volume":"10","author":"L Letinier","year":"2019","unstructured":"Letinier L, Cossin S, Mansiaux Y et al (2019) Risk of drug-drug interactions in out-hospital drug dispensings in France: results from the DRUG-Drug interaction prevalence study. Front Pharmacol 10:265","journal-title":"Front Pharmacol"},{"issue":"2","key":"2952_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1592\/phco.29.2.138","volume":"29","author":"SE Harpe","year":"2009","unstructured":"Harpe SE (2009) Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy. 29(2):138\u2013153","journal-title":"Pharmacotherapy."},{"issue":"6","key":"2952_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/fcp.12214","volume":"30","author":"A Palmaro","year":"2016","unstructured":"Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M (2016) Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 30(6):616\u2013624","journal-title":"Fundam Clin Pharmacol."},{"issue":"4","key":"2952_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323\u2013337","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 4","key":"2952_CR14","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, Maura G, Caillol H, Tajahmady A, Coste J, Gissot C, Weill A, Fagot-Campagna A (2017) Value of a national administrative database to guide public decisions: from the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique 65(Suppl 4):S149\u2013Ss67","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2952_CR15","unstructured":"French National Agency for Medicines and Health Products Safety. Thesaurus des interactions m\u00e9dicamenteuses. Published March 2018"},{"issue":"1","key":"2952_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cpt.277","volume":"99","author":"S Hennessy","year":"2016","unstructured":"Hennessy S, Leonard CE, Gagne JJ, Flory JH, Han X, Brensinger CM, Bilker WB (2016) Pharmacoepidemiologic methods for studying the health effects of drug-drug interactions. Clin Pharmacol Ther 99(1):92\u2013100","journal-title":"Clin Pharmacol Ther"},{"key":"2952_CR17","unstructured":"WHO Collaborating centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/. Accessed March 28, 2019"},{"key":"2952_CR18","unstructured":"WHO Collaborating centre for Drug Statistics Methodology. ATC\/DDD Index 2019. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed March 28, 2019"},{"issue":"4","key":"2952_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/pds.1304","volume":"16","author":"H Tobi","year":"2007","unstructured":"Tobi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LT (2007) Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 16(4):405\u2013411","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7310","key":"2952_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1136\/bmj.323.7310.427","volume":"323","author":"J Merlo","year":"2001","unstructured":"Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, Melander A (2001) Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. Bmj. 323(7310):427\u2013428","journal-title":"Bmj."},{"issue":"3","key":"2952_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/02813439308994827","volume":"11","author":"R Linnarsson","year":"1993","unstructured":"Linnarsson R (1993) Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care 11(3):181\u2013186","journal-title":"Scand J Prim Health Care"},{"issue":"5","key":"2952_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, le Couteur D, Rigby D, Gnjidic D, del Mar CB, Roughead EE, Page A, Jansen J, Martin JH (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175(5):827\u2013834","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2952_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/j.1553-2712.2000.tb00483.x","volume":"7","author":"MI Langdorf","year":"2000","unstructured":"Langdorf MI, Fox JC, Marwah RS, Montague BJ, Hart MM (2000) Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 7(11):1321\u20131329","journal-title":"Acad Emerg Med"},{"issue":"15","key":"2952_CR24","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/ajhp\/56.15.1524","volume":"56","author":"RA Weideman","year":"1999","unstructured":"Weideman RA, Bernstein IH, McKinney WP (1999) Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 56(15):1524\u20131529","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"2952_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00005650-200212000-00004","volume":"40","author":"PA Glassman","year":"2002","unstructured":"Glassman PA, Simon B, Belperio P, Lanto A (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40(12):1161\u20131171","journal-title":"Med Care"},{"issue":"2","key":"2952_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1197\/jamia.M1809","volume":"13","author":"H van der Sijs","year":"2006","unstructured":"van der Sijs H, Aarts J, Vulto A, Berg M (2006) Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13(2):138\u2013147","journal-title":"J Am Med Inform Assoc"},{"issue":"Suppl 6","key":"2952_CR27","first-page":"vi37","volume":"66","author":"N Adriaenssens","year":"2011","unstructured":"Adriaenssens N, Coenen S, Versporten A et al (2011) European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe (1997\u20132009). J Antimicrob Chemother 66(Suppl 6):vi37\u2013vi45","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2952_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1472-8206.2008.00661.x","volume":"23","author":"S Gaubert","year":"2009","unstructured":"Gaubert S, Vie M, Damase-Michel C, Pathak A, Montastruc JL (2009) Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption. Fundam Clin Pharmacol 23(2):247\u2013252","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"2952_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/bcp.13564","volume":"84","author":"K Hider-Mlynarz","year":"2018","unstructured":"Hider-Mlynarz K, Cavalie P, Maison P (2018) Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol 84(6):1324\u20131334","journal-title":"Br J Clin Pharmacol"},{"key":"2952_CR30","unstructured":"French National Agency for Medicines and Health Products Safety. Prise en charge des douleurs de l\u2019adulte mod\u00e9r\u00e9e \u00e0 intenses \u2013 Mise au point http:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/a6497f74fc2f18e8db0022973f9327e1.pdf. Published August 4, 2011. Accessed December 20, 2019"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02952-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T23:18:01Z","timestamp":1625613481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02952-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02952-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"National Institute for Health and Medical Research (INSERM) agreement for the research protocol was given in 2017-11-15. Neither ethics committee authorization nor request to national commissions for individual data protection is required according to French law to access this kind of anonymous and restricted access database. Access to EGB is possible only through a secured connection to a specific server. Data are accessible online and are analyzed by the software SAS Enterprise Guide version 4.3 (Copyright \u00a9 2006\u20132010, SAS Institute Inc., Cary, NC, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}